Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16)

Seonggyu Byeon, Myoung Joo Kang, Yoon Ji Choi, Yu Jung Kim, Miso Kim, Jina Yun, Seong Yoon Yi, Jin Young Kim, Seung Tae Kim, Jeeyun Lee